Incepta & MCRI Pharmaceuticals Comes Together For Providing Protection To Children From Rotavirus

In a significant effort towards improving the healthcare scenario for every child, Incepta Pharmaceuticals, one of the leading pharmaceutical companies in Bangladesh, & Melbourne-based MCRI Pharmaceuticals have announced a groundbreaking partnership with a goal of combating rotavirus infections in children. This collaboration seeks to provide greater access to rotavirus vaccines, specifically in developing regions, to curb the high mortality rate related to the virus. Rotavirus is a leading cause of severe diarrhoea and dehydration among infants and young children. It claims the lives of hundreds of thousands of children annually all over the world, particularly in low-income countries. This joint initiative is poised to make a substantial impact by facilitating the distribution and availability of affordable vaccines.

Dr. Abdul Muktadir, Chairman of Incepta Pharmaceuticals, emphasised the urgency of addressing rotavirus in countries with limited healthcare resources. He said that "We are proud to partner with MCRI in this groundbreaking endeavour. Together, we are committed to leveraging our expertise and resources to ensure that the rotavirus vaccine (RV3-BB) reaches the millions of children who need it most, safeguarding the health of future generations.”In the early 1980s, RV3-BB, the rotavirus vaccine was originally derived & developed from a naturally occurring human strain of rotavirus found in Melbourne by Professor Ruth Bishop AC and her team. It provides early protection against dehydrating diarrhoea from birth. This vaccine is specifically developed for neonatal or infant dosing within the routine Expanded Program on Immunization and has the potential to save hundreds of thousands of children's lives each year. 

Andrew Steer, MCRI's Professor & the director of infection, immunity and global health, said that "This collaboration represents a significant step forward in our mission to protect vulnerable children from the effects of rotavirus infection. By joining forces with Incepta Pharmaceuticals, we are poised to make RV3-BB readily available to communities in need worldwide. MCRI's relentless pursuit of accessible and scalable vaccine solutions underscores our commitment to global health equity."